Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Chinese PLA General Hospital
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07138547CT.gov GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma | — | Recruiting | — | — | — |
NCT07048353CT.gov CD30 CAR-T in the Treatment of CD30 Positive Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07453446CT.gov Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma | — | Withdrawn | — | — | — |
NCT06430736CT.gov PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) | — | Recruiting | — | — | — |
NCT06532643CT.gov Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma | — | Recruiting | — | — | — |
NCT05320081CT.gov Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma | — | Unknown | — | — | — |
NCT04556266CT.gov A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies | — | Withdrawn | — | — | — |
NCT03602157CT.gov Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | — | Active Not Recruiting | — | — | — |
NCT02690545CT.gov Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | — | Active Not Recruiting | — | — | — |
NCT02663297CT.gov Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chimeric Antigen Receptor Modified T Cells Infusion (this asset) | Chinese PLA General Hospital | P2 | B · 61 |
| Vinblastine | Intensity Therapeutics, Inc. | P4 | BBB |
| Prednisolone | The Lymphoma Academic Research Organisation | P4 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BB |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Bleomycin | Shandong Provincial Hospital | P4 | BB |
| Methotrexate | University of Chicago | P4 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Isocyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | P3 | BB |
+42 more in the Lymphoma cohort
Other indications for Chimeric Antigen Receptor Modified T Cells Infusion
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2 | B · 59 |
| Lymphoid Leukemia | — | P2 | CCC · 53 |
| HER2 Positive Breast Carcinoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Chimeric Antigen Receptor Modified T Cells Infusion in Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chimeric-antigen-receptor-modified-t-cells-infusion-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →